Here are the 424B prospectus supplements from Latigo Biotherapeutics, Inc. (LTGO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LTGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LTGO filings page.
Latigo Biotherapeutics, Inc. (symbol LTGO) is conducting an initial public offering of 19,200,000 shares of common stock at $18.00 per share, for a gross offering size of $345.6 million, plus a 30‑day underwriters’ option to buy up to 2,880,000 additional shares. Net proceeds are estimated at $315.7 million, to fund Phase 3 development and NDA submission for acute pain candidate LTG‑001, Phase 2–3 development of chronic pain candidate LTG‑321, advancement of early‑stage Nav1.8 inhibitor LTG‑418, and general corporate purposes.
Latigo is a clinical‑stage company developing non‑opioid Nav1.8 inhibitors for acute and chronic musculoskeletal pain, with LTG‑001 showing positive abdominoplasty trial results and LTG‑321 in a Phase 2 osteoarthritis trial. The company reported a $109.2 million net loss in 2025 and had an accumulated deficit of $266.1 million, with auditors including a going‑concern explanatory paragraph.